Consensus Statements of the American College of Veterinary Internal Medicine (ACVIM) provide the veterinary community with up-to-date information on the pathophysiology, diagnosis, and treatment of clinically important animal diseases. The ACVIM Board of Regents oversees selection of relevant topics, identification of panel members with the expertise to draft the statements, and other aspects of assuring the integrity of the process. The statements are derived from evidence-based medicine whenever possible and the panel offers interpretive comments when such evidence is inadequate or contradictory.
| INTRODUCTION
The panel adopted the following scheme, adapted from the American Heart Association, 1 to rate the strength of the recommendations in these guidelines. The recommendation class designation appears with each recommendation, along with a second term that independently rates the quality of the evidence upon which the recommendation was based.
| CLASSIFICATION OF RECOMMENDATIONS
Class I recommendations are strong, reflecting the panel's conviction that the recommended action appears to have definite benefit for most patients, outweighing the risk to most patients.
Class I recommendations can be summarized as "benefit >>> risk".
Class IIa recommendations are moderately strong, reflecting the panel's belief that the recommended action should benefit most patients, probably outweighing the risk to most patients.
Class IIa recommendations can be summarized as "benefit >> risk".
Class IIb recommendations are weak, reflecting the belief that the recommended action possibly benefits some patients and may outweigh the risk of taking the proposed action in most patients.
Class IIb recommendations can be summarized as "benefit > risk".
Class III is used to describe recommendations in which the panel believes that the potential risk and benefit of the proposed action are essentially equal, such that these actions should probably not be pursued under most circumstances.
Class III recommendations can be summarized as "benefit = risk".
Class IV recommendations indicate the panel's belief that the proposed action is more likely to cause harm than benefit to most patients, such that Class IV designates actions that the panel believes are contraindicated under most circumstances.
Class IV recommendations can be summarized as "risk >> benefit".
The recommendation classification and level of evidence (LOE) upon which that recommendation was based were independently determined by the panel (ie, any class of recommendation may be paired with any LOE).
The panel acknowledges that future evidence may change the strength of any of these recommendations, as well as the quality of the evidence on which they are based. Many important clinical questions addressed in the guidelines have not yet been adequately addressed by clinical trials. At times, the panel has made strong recommendations based on more than the available evidence-thus weak or even absent evidence does not necessarily accompany a weak recommendation.
Although randomized clinical trial evidence may be unavailable, a clear clinical consensus that a particular test or treatment is useful may exist.
| LEVELS OF EVIDENCE
The methods of assessing the quality of the scientific evidence that supports clinical decision making are evolving. The panel chose to use a hybrid of the American Heart Association and Veterinary Emergency Critical Care RECOVER evidence grading criteria, as outlined below.
1,2
| Strong
High-quality evidence is from ≥1 randomized controlled trial, or a moderate-quality randomized controlled trial, corroborated by a highquality observational study or other moderate-quality trials. These prospective clinical studies were performed in dogs and either randomly allocated subjects to an intervention or control group or used concurrent controls (ie, controls recruited at the same time as the experimental subjects) without randomization. Strong evidence also could have been obtained from prospectively enrolled, controlled, observational clinical studies in dogs with spontaneously occurring mitral valve disease. These studies asked clinically relevant questions, were considered to be adequately powered, and did not experience excessive loss of subjects to follow up in any group, generating a clear and statistically valid result.
| Moderate
Moderate-quality evidence is from ≥1 well-designed, well-executed nonrandomized studies, observational studies, or registry studies, or meta-analyses of such studies. Evidence rated as "moderate" by the panel was generated from controlled, retrospective studies in dogs (ie, studies in which dogs with mitral valve disease [or appropriate controls] were selected from a previous period in time). Moderate evidence also could have been generated from blinded and controlled laboratory studies that were performed in experimental dogs.
| Weak
Weak-quality evidence is from randomized or nonrandomized observational or registry studies with limitations of design or execution, but performed in dogs with clinical myxomatous mitral valve disease (MMVD), or physiological, mechanistic, or experimental studies performed in research dogs. Evidence rated as "weak" by the panel was generated from uncontrolled clinical case reports or case series in dogs with mitral valve disease, as well as by experimental or clinical studies that were not performed in dogs with MMVD. These could include experimental models of mitral valve disease in other species, as well as high-quality studies in humans (such as meta-analyses, randomized controlled trials, and clinical studies with concurrent controls, including observational studies) with spontaneous mitral valve disease.
| Expert opinion
Expert opinion based on clinical experience, common sense, or physiologic or mechanistic studies performed in species other than dogs is considered the weakest LOE.
| INCIDENCE, PATHOLOGY, AND PATHOGENESIS OF MMVD
It is estimated that approximately 10% of dogs presented to primary care veterinary practices have heart disease, and MMVD is the most common heart disease of dogs in many parts of the world, accounting for approximately 75% of heart disease cases seen in dogs by veterinary practices in North America.
The pathology of MMVD has been relatively recently reviewed, 3 and some progress in understanding the genetics and pathophysiology of the disease has been reported. 4, 5 Myxomatous mitral valve disease most commonly affects the left atrioventricular or mitral valve, although in at least 30% of cases, the right atrioventricular (tricuspid) valve also is involved. 6 The disease is approximately 1.5 times more common in males than in females. Prevalence is also higher in smaller (<20 kg) dogs, although large breeds sometimes are affected, and larger dogs also often experience faster disease progression with more apparent myocardial dysfunction, and have a more guarded prognosis. 7 In small breed dogs, the disease generally is slowly but at times unpredictably progressive. Most dogs experience the onset of a recognizable murmur of mitral valve regurgitation years before the clinical onset of heart failure.
Cavalier King Charles Spaniels notably are predisposed to developing MMVD at a relatively young age, although the time course of their disease progression to heart failure does not appear to be markedly different from that of other small breed dogs. 8, 9 Although the cause of MMVD remains unknown, the disease has an inherited component in some breeds, 5, 10 properties of activated myofibroblasts, and activated myofibroblasts increase proteolytic enzymes, including matrix metalloproteinases, which degrade collagen and elastin faster than they can be produced by unactivated valvular interstitial cells. [13] [14] [15] Endothelial cell changes and subendothelial thickening also occur, [16] [17] [18] but these changes do not appear to put dogs with MMVD at increased risk for either arterial thromboembolism or infective endocarditis. Mitral valve prolapse is a common finding in dogs with myxomatous valve degeneration and represents a prominent echocardiographic feature of MMVD in some breeds. 10, 19, 20 Progressive deformation of the valve structure eventually prevents effective coaptation, allowing regurgitation (valve leakage). Progressive valvular regurgitation increases cardiac work, leading to ventricular remodeling (eccentric hypertrophy of both the atrium and ventricle, and intercellular matrix changes), and eventually to ventricular dysfunction.
It has been hypothesized that abnormal numbers or types of mitogen receptors (ie, any of the subtypes of serotonin, endothelin, or angiotensin receptors) on fibroblast cell membranes in the valves of affected dogs play a role in the pathophysiology of acquired valvular lesions. [21] [22] [23] Systemic or local metabolic, neurohormonal, or inflammatory mediators (eg, endogenous catecholamines, inflammatory cytokines) also may influence progression of the valve lesion or the subsequent myocardial remodeling and ventricular dysfunction that accompany long-standing, hemodynamically important valvular regurgitation. The interactions of these factors, as well as the impact of changes in mitral valve annular geometry and mechanical stress on the pathogenesis and progression of MMVD, are incompletely understood. [11] [12] [13] 24 The prevalence of MMVD increases markedly with age in small breed dogs, with up to 85% showing evidence of the valve lesion by 13 years of age. 25 The presence of the pathologic lesion of MMVD in an individual does not necessarily identify a dog that will develop clinically relevant valve regurgitation or signs of heart failure. Depending heart rate are at least moderately predictive of the rate of progression of MMVD and can help identify dogs at risk for impending heart failure. [26] [27] [28] [29] The rate of change of echocardiographic and radiographic variables also may identify animals at increased risk of heart failure or death from cardiac cause. 30, 31 Development of truly predictive (sensitive and specific) risk stratification schemes, however, awaits further refinement.
| CLASSIFICATION OF HEART DISEASE AND HEART FAILURE
The term heart disease is used synonymously with cardiac pathologyin this case, myxomatous degenerative changes of the mitral valve.
Heart disease, depending on its nature, rate of progression, and patient age and condition may or may not lead to heart failure. The term "heart failure" refers to clinical signs caused by heart dysfunction. Heart failure is caused by heart disease that affects heart function such that either venous pressures increase so severely that fluid accumulates in the lungs or a body cavity (congestive heart failure [CHF], sometimes called "backward heart failure because the heart fails to drain the veins adequately), or the heart's pumping ability is compromised such that it cannot meet the body's needs either during exercise or at rest, in the face of either normal or increased venous pressures (sometimes called "forward heart failure").
In 2009, the consensus panel adapted a staging system for heart disease and heart failure, and sought to link the severity of morpho- This staging system for MMVD describes 4 basic stages of heart disease and heart failure:
• Stage A identifies dogs at high risk for developing heart disease but that currently have no identifiable structural disorder of the heart (eg, every Cavalier King Charles Spaniel or other predisposed breed without a heart murmur).
• should benefit from initiating pharmacologic treatment to delay the onset of heart failure (specific criteria detailed below).
• Stage C denotes dogs with either current or past clinical signs of heart failure caused by MMVD. Because of important treatment differences between dogs with acute heart failure requiring hospital care and those in which heart failure can be treated on an outpatient basis, these issues have been addressed separately by the panel. It is important to note that some dogs presented with heart failure for the first time may have severe clinical signs requiring aggressive treatment (eg, with additional afterload reducers or temporary ventilatory assistance) that more typically would be reserved for those patients refractory to standard treatment (see Stage D below).
• This staging system emphasizes that there are known risk factors and structural prerequisites for the development of heart failure caused by MMVD. Accordingly, the classification system is designed to aid in:
• developing screening programs for the presence of MMVD in dogs known to be at risk;
• implementing interventions that may (now and in the future) decrease the risk of disease development or progression;
• identifying asymptomatic dogs with MMVD early in the course of their disease, comparable to in situ cancer, so they can be more effectively managed medically as chronic disease patients, or possibly be treated surgically;
• identifying symptomatic dogs with MMVD so that these patients can be managed medically as chronic disease patients or possibly treated surgically; and
• identifying symptomatic dogs with advanced heart failure caused by MMVD refractory to conventional medical treatment. These patients require aggressive or new treatment strategies, possibly including surgery, or potentially palliative or hospice-type end-of-life care.
| GUIDELINES FOR DIAGNOSIS AND TREATMENT OF MMVD

| Stage A
Dogs at higher than average risk for developing heart failure but without any apparent structural abnormality (ie, no audible heart murmur)
at the time of examination. 
| Recommendations for diagnosis and further categorization of Stage B
• Myxomatous mitral valve disease typically is recognized during a screening or routine health examination by auscultation of a heart murmur typical of mitral valve regurgitation.
• Thoracic radiography is recommended in all patients to assess the hemodynamic relevance of the valve disease and to obtain baseline thoracic radiographs at a time when the patient is asymptomatic for • Blood pressure measurement is recommended for all patients to identify or rule out concurrent systemic hypertension and to estab- 6.3 | Stage B1: Asymptomatic dogs with mitral valve regurgitation caused by MMVD that is not severe enough to meet criteria used to trigger the use of medical treatment to delay the onset of heart failure. 43, 44 Dogs in this category should meet the current criteria outlined below.
• Stage B2 criteria for heart enlargement identify dogs that are likely to benefit substantially from treatment before the onset of clinical signs of heart failure. (Table 1) 46 ; breed-adjusted [47] [48] [49] [50] [51] [52] [53] radiographic vertebral heart score (VHS) >10.5.
• Ideally, all these criteria should be met before initiating treatment, because treatment represents a lifelong commitment. Of these criteria, echocardiographic evidence of left atrial and ventricular enlargement meeting or exceeding these criteria is considered to be the most reliable way to identify dogs expected to benefit from treatment.
• Although studies to identify reliable radiographic markers of Stage • Beta blockade is not recommended routinely to delay the onset of heart failure in dogs in Stage B2, regardless of heart enlargement. For dogs weighing between 1 and 20 kg (BW, left hand column), the left ventricular end diastolic diameter (LVIDD) meeting this criterion must be more than or equal to the dimension (in cm) in the right hand column. In the referenced clinical trial, the end-diastolic LV dimension was obtained from a 2D short-axis-guided M-mode echocardiogram of the chamber. 55 The formula for normalizing LVIDD to BW is LVIDdN = LVIDd (cm)/weight (kg) 
| Recommendations for diagnosis of Stage C
The signalment, history, and physical examination can be helpful in determining the pretest probability of heart failure as a cause of clinical signs in patients with MMVD. For example, obese dogs with no history of weight loss are less likely to be in heart failure secondary to MMVD; dogs with marked sinus arrhythmia and relatively slow heart rates also • For life-threatening pulmonary edema (ie, expectoration of froth associated with severe dyspnea, radiographic white-out lung, poor initial response to furosemide bolus with failure of respiratory effort and rate to improve over 2 hours), furosemide also may be administered as a constant rate infusion (CRI) at a dosage of 0.66-1 mg/kg/ hour after the initial bolus. 66, 67 (Class IIa, LOE: weak)
• Allow the patient free access to water once diuresis has begun. • Participation in a structured, home-based extended care program to promote ideal BW, appetite, respiratory and heart rate monitoring while providing client support to enhance medication regimen adherence and dosage adjustments in patients with heart failure is encouraged. (Class I, LOE: expert opinion)
Of these variables, identification of increases in resting respiratory rate above normal baseline has the best predictive value for impending clinical decompensation. 78, 79 (Class I, LOE: moderate).
• In centers with low complication rates, Stage C patients benefit from surgical intervention to repair their mitral valve apparatus. 61, 63 (Class I, LOE: moderate)
• In cases complicated by atrial fibrillation, diltiazem, often in combination with digoxin (see below), is recommended to control ventricular rate. Multiple preparations of diltiazem are available; treatment should be started at a modest dosage for the preparation chosen and titrated to achieve heart rate control. Ideally, mean heart rate as measured by Holter monitoring in dogs with well-controlled signs of CHF receiving stable drug dosage regimens should be close to normal or at least <125 beats per minute. 80, 81 (Class I, LOE: moderate)
• Digoxin 0.0025-0.005 mg/kg, administered PO q12h to achieve a target steady-state plasma concentration (approximately 8 hours post-pill) of 0.8-1.5 ng/mL. For the chronic management of Stage C heart failure, panelists recommended the addition of digoxin only in cases complicated by persistent atrial fibrillation to slow the ventricular response rate. In these cases, digoxin generally is used in combination with diltiazem. Digoxin may not be tolerated in patients with factors known to put animals at risk for adverse effects or toxicity (eg, increases of serum creatinine concentration above normal, ventricular ectopy, concerns over owner adherence, or chronic gastrointestinal disease resulting in frequent or unpredictable bouts of vomiting or diarrhea). 82 (Class IIb, LOE: moderate)
• In patients receiving a beta blocker before the onset of Stage C heart failure, the majority of panelists continue beta blockade; some panelists consider dosage reduction if needed clinically because of clinical signs of low cardiac output, hypothermia, or bradycardia.
(Class IIB, LOE: expert opinion)
• Some panelists find the use of cough suppressants useful in occasional patients in Stage C heart failure from MMVD. (Class IIa, LOE: expert opinion)
• Some panelists find the use of bronchodilators useful in occasional patients in Stage C MMVD patients. (Class IIb, LOE: expert opinion)
| Recommendations for dietary treatment for Stage C
• Cardiac cachexia is defined as a loss of muscle or lean body mass associated with heart failure, with or without clinically relevant accompanying weight loss. Cachexia has substantial negative prognostic implications and is much easier to prevent than to treat. 83, 84 (Class I, LOE: moderate)
• Maintain adequate calorie intake (maintenance calorie intake in Stage C should be approximately 60 kcal/kg BW) to minimize weight loss that often occurs in CHF. 85, 86 Simple culinary strategies to improve appetite may be beneficial in accomplishing this goal (eg, warming food, mixing wet food with dry food, offering a variety of foods). (Class I, LOE: moderate)
• Specifically address and inquire about the occurrence of anorexia and make efforts to treat any drug-induced or other identifiable causes of anorexia that occur. (Class I, LOE: expert opinion)
• Record body condition score and accurate weight of the patient at every clinic visit and investigate the cause of clinically relevant changes in body condition, weight gain or loss. (Class I, LOE: expert opinion)
• Ensure adequate protein intake and avoid low-protein diets designed to treat chronic kidney disease, unless severe concurrent renal failure is present. 83 (Class I, LOE: moderate)
• Modestly restrict sodium intake, taking into consideration sodium from all dietary sources (including dog food, treats, table food, and foods used to administer medications) and avoid any processed or other salted foods. 87, 88 (Class I, LOE: moderate)
• Monitor serum electrolyte concentrations and supplement the diet with potassium from either natural or commercial sources only if hypokalemia is identified. The panel's anecdotal experience is that hypokalemia is much more common in animals receiving torsemide.
(Class I, LOE: expert opinion)
• Hyperkalemia is relatively rare in patients treated for CHF with diuretics, even in those concurrently receiving ACEI in combination with spironolactone. Diets and foods with high potassium content should be avoided when hyperkalemia is present. (Class I, LOE:
expert opinion)
• Consider monitoring serum magnesium concentrations, especially as heart failure progresses and in dogs with arrhythmias. Supplement with magnesium in cases in which hypomagnesemia is identified. (Class IIa, LOE: expert opinion)
• Consider supplementing with omega-3 fatty acids, especially in dogs with decreased appetite, muscle loss, or arrhythmia. 86 These drugs are recommended in addition to an ACEI and pimobendan. Vigilance is needed to avoid serious, prolonged hypotension (monitor blood pressure closely, maintaining arterial systolic blood pressure >85 mm Hg, or mean arterial blood pressure >60 mm Hg). Serum creatinine concentration should be reevaluated no more than 24 to 72 hours after initiating these drugs.
The panel emphasized that because afterload reduction may increase cardiac output substantially in the setting of severe MR and heart failure, administration of an effective arterial dilator drug in this setting does not necessarily compromise blood pressure.
(Class IIa, LOE: expert opinion).
• Sildenafil, (starting at 1-2 mg/kg PO q8h, and titrating if needed) is used by panelists to treat Stage D heart failure from MMVD that is complicated by clinically relevant estimated pulmonary hypertension.
Pulmonary hypertension is recognized as an increasingly frequent complication of MMVD, either as a direct consequence of severe mitral valve regurgitation or as an independent comorbidity that can be responsible for clinical signs including syncope, cough, and shortness of breath (dyspnea), and sometimes radiographically evident pulmonary infiltrates. (Class IIa, LOE: expert opinion)
• Torsemide, a potent and longer-acting loop diuretic, may be used to treat dogs no longer adequately responsive to furosemide (torsemide beginning dosage of 0.1-0.2 mg/kg PO, or approximately 5%-10% of the current furosemide dosage, up to approximately 0.6 mg/kg, divided q12h if necessary). 94 (Class I, LOE: moderate)
• Spironolactone, if not already started as recommended in Stage C, is indicated for chronic treatment of Stage D patients. 74 (Class I, LOE: moderate)
• Beta blockers generally should not be initiated at this stage, unless they are being used as an adjunct to control heart rate in atrial fibrillation. (Class IV, LOE: expert opinion)
• Hydrochlorothiazide was recommended by several panelists as adjunctive treatment to furosemide or torsemide, utilizing various dosing schedules (including intermittent use every 2nd-4th day).
Some panelists warned of the risk of acute kidney insufficiency and marked electrolyte disturbances, based on personal experience. (Class IIb, LOE: expert opinion)
• Pimobendan dosage is increased by some panelists to include a third 0.3 mg/kg daily dose (off-label use; routine explanations and cautions to the owner apply as in hospital care described above) or an even higher dosage when repeated rescue is necessary. (Class IIa, LOE: expert opinion)
• Additional afterload reduction, using either amlodipine or hydralazine (see dosages and cautions above), may provide additional hemodynamic benefit and decrease cough frequency.
• Digoxin, at the same (relatively low) dosages recommended by some panelists for Stage C heart failure with atrial fibrillation, is recommended for the treatment of atrial fibrillation in Stage D patients lacking a concrete contraindication. 82 (Class IIb, LOE: moderate)
• Digoxin, at the same (relatively low) dosages recommended by some panelists for Stage C heart failure with atrial fibrillation, also is recommended by some panelists for all Stage D patients, including those in sinus rhythm, lacking a concrete contraindication.
(Class IIb, LOE: expert opinion)
• Sildenafil (1-2 mg/kg PO q8h) may be useful in the management of patients with clinical signs related to exertion and in management of ascites when there is echocardiographic evidence of moderate to severe pulmonary hypertension. 95 (Class IIa, LOE: weak)
• Beta blockade may be useful in decreasing the ventricular response rate in atrial fibrillation after stabilization and digitalization, but caution should be used because of the negative inotropic effects of beta blockers. (Class IIb, LOE: expert opinion)
• The majority of panelists felt that beta blockade initiated previously should not be stopped, but that dosage reduction may be 
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